



Investor News no. 2/2007

To OMX Nordic Exchange Copenhagen

Copenhagen, November 5, 2007

Investor News: Curalogic will present at the Acumen BioFin Rodman & Renshaw Conference in New York

Curalogic A/S (OMX: CUR) will attend at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 5-7, 2007 in New York.

The presentation will be held by Peter Moldt, Ph.D., President and Chief Executive Officer of Curalogic and is scheduled for:

Monday 3:45PM local time on November 5, 2007.

The PowerPoint presentation and a audio and archived webcast will be available at www.curalogic.com.

Yours sincerely

Curalogic A/S

For additional information, please contact:

Peter Moldt, President and CEO

Tel +45 99 99 24 00, mobile +45 2625 0422

Helle Busck Fensvig, EVP and CFO

Tel +45 99 99 24 00, mobile +45 2070 5537

About Curalogic

Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the treatment of allergy. By combining the best of two worlds - the efficacy of immunotherapy combined with the safety and patient convenience of symptomatic treatments – Curalogic aims to develop a novel and user-friendly form of allergy treatment, and make it the preferred type of allergy treatment among patients. Curalogic has a broad and mature pipeline with a product for treatment of ragweed allergy in Phase III, a product for treatment of grass allergy ready for Phase III, a product for treatment of cat allergy in Phase II and a product for treatment of house dust mite allergy preparing for clinical trials.